Evogene (EVGN) announced an expanded phase of its collaboration with Google (GOOG) Cloud. Under this new phase, the collaboration will focus on developing and integrating advanced AI Agents into Evogene’s ChemPass AI platform, its proprietary engine for small-molecule discovery and optimization, using Google Cloud’s Vertex AI platform. The goal is to increase the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development. This announcement marks the second milestone in the partnership between Evogene and Google Cloud, following the collaboration focused on building a generative AI foundation model that now serves as a core component of ChemPass AI.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVGN:
- Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement
- Evogene’s Biomica Grants Lishan Biotech Global Rights to Microbiome Cancer Drug BMC128
- Biomica and Lishan Biotech sign licensing agreement for BMC128
- Evogene Announces CFO Resignation and Finance Leadership Transition
- Evogene, Unravel Biosciences announce scientific collaboration